Pfizer may not be the best investment in coming months, as doubts surface about the company's near-term prospects in the absence of M&A.
The company has spent $600 million weighing a potential breakup.
The $639 million deal marks the the third purchase for Brent Saunders since early August.
Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.